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INTRODUCTION 
 
 
 Pregnancy is an unique metabolic state in which, the mother has to 
provide fuel not only for herself but also for the metabolic needs of the 
conceptus. To accomplish this certain physiological changes. (especially is 
glucose metabolism) and women with preexisting aberration in insulin 
economics or preexisting decline in B cell function develop GDM (CURET 
et al). 
 Normal pregnancy is an insulin resistant state mediated by placental 
anti-insulin hormones. If the maternal pancreas cannot increase production 
of insulin to sustain normoglycemia despite these anti insulin hormones 
gestational diabetes occurs.  
 Gestational diabetes is a commonest metabolic disorder in 
pregnancy. Incidence varies between 3 to 12% depending on the sample 
population and diagnostic criteria used.  
 The name gestational diabetes mellitus was recommended by 
American college of obstetricians and gyenaecologists in the second 
international workshop conference on gestational Diabetes Mellitus in 
Chicago on October  25th 1984, replacing the names impaired glucose 
tolerance in pregnancy (RUST, JAMES et al). 
 Gestational diabetes mellitus and other categories of glucose 
intolerance during pregnancy are one of the causes for increased perinatal 
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mortality and maternal mortality. As pregnancy proceeds the prevention of 
maternal complication and perinatal mortality and morbidity required 
continued normalization of metabolism and close surveillance of the fetal 
condition.  
 Hence it is mandatory that universal screening of all pregnant 
subjects must be undertaken to detect abnormal glucose tolerance during 1st 
and 2nd trimester for early detection and effective management.  
 Decreased infant, perinatal mortality and morbidity rates have 
followed higher detection rates and more aggressive treatment of mild 
carbohydrate intolerance in pregnancy. 
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REVIEW OF LITERATURE 
 
HISTORY OF DIABETES:  
 The history of diabetes probably dates back to the beginning of 
human kind, encompassing centuries, generations and civilizations. There is 
some evidence that Hippocrates was familiar with diabetic conditions. In 
the writing of Hippocrates, a word is used that is translated to mean “to 
make water much often”. 
 It was areteaus of cappadocia (30-0 AD) who named diabetes which 
means to pass through or to siphon. He described diabetes as an affilction 
being a melting down of the flesh and limbs into urine.  
 
DIABETES IN PREGNANCY: 
 Before 1856, there is hardly any report of pregnancy complicating 
diabetes. Bloh wrote that “true diabetes is inconsistent with conception”. In 
1882, for the first time Duncan reported 22 pregnancies with diabetes in the 
literature of which 27% of mothers died at the time of labor and 22% died 
during the following 2 years. This trend of high maternal and fetal mortality 
continued until the discovery of insulin.  
 The advent of insulin brought about a dramatic change in the overall 
outlook for diabetic women and their reproductive potential. There was a 
dramatic fall in the maternal mortality from 45% to just over 2% shortly 
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after the introduction of insulin. However, the perinatal mortality did not 
rapidly change, but slowly decreased over time. The continuing problems 
are neonatal hypoglycemia, congenital malformations, infections, 
macrosomia and traumatic injuries to the fetus during parturition.  
1. Korean J Lab med. 2009 Apr; 29 (2): 110-5 the relationship between 
the timing of gestational diabetes screening and HbA1C level and neonatal 
outcome.  
2. Zhong Narda xue xue ba yi xue ban 2008 Jan; 33(1); 85.8 
Glycosylated hemoglobin test in gestational abnormal glucose metabolism. 
3. Diaabetes Res din prae 2007 Sep. 77 43) 465 to Epub 2007 mar 9  Can 
plasma glucose & HbA1c predict fetal growth in mothers with different 
glucose tolerance levels.  
4. Standardisation of the reference method for the measurement of HbA1c 
to improve diabetes care (PDF). The association for clinical biochemistry 
and diabetes UK April 2008. htt pry W-WW acb. org. uk/docs/tibalc.pdf.  
5. The international expert committee (2009) international expert committee 
report on the role of the AIC assay in the diagnosis of diabetes Diabetes 
care 32 (7) 1327-1334 doi :102337/dc09 9033: PMLD 19502545. 
 
DEFINITION: 
 Gestational diabetes mellitus is defined as carbohydrate intolerance 
of variable severity with onset or first recognition during pregnancy. the 
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definition applies regardless of whether or not insulin is used for treatment 
(American Diabetes Association 1995). 
Gestational diabetes mellitus affects 1-2% of all pregnancies.  
 
MATERNAL GLUCOSE HOMEOSTASIS:  
 Both in early and late pregnancy the glucose concentration stays 
constant between 4 & 4.5 mmol/l except after meals. This degree of 
homeostasis is only maintained by doubling the secretion of insulin from 
the end of first to the third trimester of pregnancy.  
 Insulin resistance develops although the aetiology remains uncertain. 
Review by Kuhl concluded that pregnancy induced insulin resistance was 
likely to be a post receptor defect. This effect is mediated by increased 
production of one or more of free cortisol which is elevated in pregnancy 
associated hormones or of free cortisol which is elevated in pregnancy. 
Withholding food from pregnant women results in a much earlier recourse 
to breakdown of triglyceride, leading to increased concentration of 
circulatory free fatty acids and ketone bodies, described by Freinkel as 
“accelerated starvation.  
 As a result of the physiologic changes of pregnancy normal fasting 
blood sugar is 65+/- 9mg /dl. The mean random blood sugar level is 80+ 10 
mg /d 1. Post prandial elevation never exceed 140 mg/dl.  
 
11 
 
Pathophysiology of Gestational Diabetes mellitus: 
 With implantation of the trophoblast the production of pregnancy 
related hormones begins. These hormones immediately alter the metabolism 
of nutrients to shift the priority of metabolic products towards the growing 
fetus. A buffering mechanism must be initiated early in pregnancy to 
prevent the mother from suffering deleterious hypoglycemia between 
feedings as her reserve continue to flow to her unborn child.  
 Human chorionic gonadotrophin, the initial hormone secreted by the 
syncytiotrophoblast in early pregnancy does not have an effect on glucose 
homeostasis.  
 Estrogens which  rise within 35 days of conception have weak 
antiinsulin properties and also have a relative diabetogenic potency. As 
cortisol binding globulin is increased, the maternal adrenal gland secretes 
more cortisol resulting in an increase in the level of free cortisol. 
Hypercortisolemia causes maternal insulin resistance, delayed glucose 
clearances, and thus more available glucose for fetal use. The appearance of 
cortisol appears timed to contribute glucose to the rising demands for fetal 
fuels. The glucose tolerance is an advantage at this point in pregnancy.  
 Prolactin and human placental lactogen have an effect on glucose 
metabolism. The effect of human placental lactogen on fat and carbohydrate 
metabolism are similar to those following treatment on growth hormone. 
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There is inhibition of peripheral glucose uptake and stimulation of insulin 
release.  
 Thus the hormonal changes early in pregnancy can be viewed as a 
serial rise in hormones intended to maintain a constant glucose supply to the 
fetus. As fetal requirements increase, the gluconeogenic properties and the 
concentration of hormones rise.  If the maternal pancreas cannot keep up 
with the insulin resistance produced by these hormones, blood glucose level 
rise which leads to gestational diabetes mellitus.  
 
Classifiation:  
 Classification of GDM is very essential in order to diagnose the 
severity of the condition and to plan the management for achieving 
euglycemia and for the assessment of prognosis of the mother and the fetus.  
 
National Diabetes  Data group classification of DM:  
1).Type – I  DM  (IDDM)    - Juvenile onset DM Ketosis prone DM  
2).Type – II DM (NIDDM)  - Brittle DM  
     Adult onset DM 
     Maturity onset DM 
     Ketosis resistant DM 
              Stable DM  
3).Type III (GCI)            -     Gestational carbohydrate intolerance. 
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Priscilla White’s classification:  
1. GDM - Discovered during pregnancy, glycemia may or may not be 
maintained by diet alone. Insulin may be required.  
2. Class-A - Discovered before pregnancy, controlled with diet alone 
any duration or any age of onset.  
3. Class-B - Age of onset 20 yrs. (or) older or duration < 10 years.  
4. Class-C - Age of onset 10 to 19 years or duration 10-19 years.  
5. Class-D - Age of onset under 10 years, duration over 20 years, 
background retinopathy.  
6. Class-R  -  Proliferative retinopathy, vitreous haemorrhage.  
7. Class-F  -  Nephropathy (over 500 mg per day proteinuria) 
8. Class-R F  -  Both R + F 
9. Class- H -  Arterio Sclerotic heart disease clinically evident.  
10. Class –T - Prior renal transplant. 
American college of obstetricians & gynecologist classification, 1986 
revised in 1994 Gestational Diabetes  
 
Class 
Fasting Plasma glucose 
mg/dl 
Post Prandial Plasma 
glucose mg/dl  
A1 <105 or <120 
A2 <105 or <120 
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Pregestational Diabetes 
Class Age of onset Duration  
(years) 
Vascular disease Therapy 
A Any Any None Diet  only 
B Over 20 <10 None Insulin 
C 10-19 10-19 None Insulin 
D Before 10 >20 Benign 
Retinopathy 
Insulin 
F Any Any nephropathy Insulin 
R Any Any Proliferative 
Retinopathy 
Insulin 
H Any Any Heart disease Insulin  
 
Epidemiology of GDM: 
 Marked variation has been reported in the prevalence of GDM world 
wide ranging from 2.1% (Korea) to 15%. 
Author (years) Subjects GDM prevalence% 
Biescheli etal (1991) Vietnam 
Chinese 
Africa 
Indian subcontinent 
7.3 
13.9 
9.4 
15 
Ranchod et al Indian 3.8 
Samanta et al Indian 0.18 
Dorrhorst et al Indian 4.4 
Agarwall et al North Indra 1.88 
Ramachandran et al South Indian 0.56 
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Effects of GDM on Mother:  
Preeclampsia: 
 Affects 10 to 25% of all pregnant diabetic patients  
Infection: 
 High incidence of chorioamnionints and postpartum endometritis 
Postpartum bleeding: 
 High incidence caused by exaggerated uterine distension 
Caesarean section: High incidence in pregnant diabetic patients. 
Effects of GDM on fetus:  
 The most common complication is macrosomia, which may affect 
upto 40% of babies, whose mothers have gestational diabetes. Common 
problems of infants of diabetic mother are hyperblirubinemia, 
hypoglycemia, hypocalcemia and hyperviscosity syndrome. Finally the 
incidence of fetal death and still birth is higher in gestational diabetic 
mother than in non-diabetic population.  
Screening in pregnancy: 
Need for screening: 
1. The great majority of women with mild degree of carbohydrate 
intolerance during pregnancy do not have signs & symptoms.  
2. Routine blood test and urine test are not reliable to diagnose 
GDM 
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3. Carbohydrate intolerance during pregnancy causes significant 
increase in fetal morbidity and mortality and maternal morbidity.  
4. Early diagnosis and treatment can prevent fetal wastage.  
Population to be screened:  
There are two schools of thought  
1. Universal screening 
2. High-risk screening  
Risk factor for screening:  
1. Obesity or BMI > 27 before pregnancy 
2. Age more than 30 years  
3. Family H/O DM 
4. History of delivery of large infant >4 kg.  
5. Previous history of stillbirth baby with congenital anomalies 
unexplained perinatal and neonatal death. 
6. H/O GDM is previous pregnancy 
7. H/O recurrent UTI, moniliasis 
8. Presence of polyhydramnios and pregnancy induced 
hypertension. 
35-50% of women with GDM will not have any risk factors. Hence 
in third international workshop conference on GDM, American Diabetology 
association recommended universal screening for all antenatal pregnant 
women.  
17 
 
Low risk: 
• Member of ethnic group with low prevalence of gestatonial diabetes.  
• No known diabetes in first degree relatives  
• Age less than 25 years. 
• No H/O abnormal glucose metabolism 
• No H/O poor obstetrical outcome  
 
Average Risk: 
 Perform blood glucose testing at 24-28 weeks. Average risk includes 
women of Hispanic, African, Native American South or East Asian origin. 
 
High Risk: 
 Perform blood glucose testing as soon as possible. If gestastional 
diabetes is not diagnosed blood glucose testing should be repeated at 24-28 
weeks or at anytime a patient has symptoms or signs suggestive of 
hyperglycemia  
• Marked obesity 
• Strong family H/o type II diabetes 
• Prior gestational diabetes 
• Glucosuria  
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Criteria for an ideal screening test:  
The test must detect the disease in a stage where early treatment will 
provide superior prognosis than diagnosing in late stage.  
 
• Must be simple to use.  
• Should be easy to perform in general population . 
• Test must be cost effective. 
• Sensitive enough to diagnose all the people, who are having the 
disease.  
• Specific enough to exclude people who are not having the disease.  
 
1. Methods of Screening:  
a. Glucose challenge test: 
 This test was adopted by 0’ Sullivan in 1973. In these test patients 
was given 50g of glucose in 200ml of water irrespective of the last meal. 
Venous blood was drawn 1 hour after drinking glucose and plasma blood 
glucose level estimated by Somogyi - Nelson method. The recommended 
threshold is 140 mg/d1. 
 Sensitivity 80% 
 Specific city 90% 
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b. 2 Hour postprandial test:  
 Patient was given 100mg of carbohydrate meal and various blood 
drawn after 2 hrs and blood glucose estimation done. The normal value is 
<120 mg/d1. 
c. Random blood sugar estimation: 
 Tornkid and MC dongall (1981) conducted a study for screening of 
antenatal women to diagnose GDM by dividing them into two groups 
within two hours of last meal or after 2 hours of last meal.  The reference 
range was  
 115 mg/d1 within 2 hrs of meal  
105 /d1 after 2 hrs of meal  
Stangenber et al 1985, Nasrat et al 1988 suggested that RBS is insensitive 
for the identification of GDM. 
d. Fasting blood sugar:  
 Normally in pregnant women fasting blood sugar will be 70 to 90 
mg/d1. Value >105mg/d1 suggest glucose intolerance. Only one third of 
GDM patient will have fasting hyperglycemia. If we take FBS as a 
screening test, other 2/3rd of GDM patients will not be diagnosed 
(METZGER BE et al, 1992).  
e. WHO testing:  
 According to WHO expert committee 75g of oral glucose load given 
(patient need not be in fasting) and single plasma glucose value estimation 
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at 2 hrs. If glucose value is more than 140 mg% a 3 hr OGTT performed. A 
75 gm 2 hrs screening test seems to be as useful in detecting GDM and is 
more suited to crowded outpatient clinics because its utility to detect GDM 
is not seriously affected by small variation in blood sampling time.  
f. Seshiah spot test:  
 Seshiah et al (1984) used a spot with reference to a previous meal 
and chose the top one percentile for full OGTT. The critical spot test 
glucose values are 85 95 105 105 95 90 mg at  30, 60, 90, 120, 150, 180 
minutes respectively in relation to the last meal.  
 
2.  Gycosylated Haemoglobin and other proteins:  
 Glycosylated haemoglobin and other protein have been proposed as 
a screening test for gestational diabetes. In HbA1C-a glucose molecule is 
attached to the N –terminal group of side chain of haemoglobin by non 
enzymatic reaction and this attachment depend on the concentration of 
sugar in the blood stream over prolonged period of time. Glycosylation is 
slow and reversible until the death of RBC’s. 
 So glycosylation in RBCs directly proportional to the amount of 
glucose over a period of time, this will reflect the blood sugar control past 2 
to 3 months.  
 Glycosylated haemoglobin was measured by a modified chemical 
method of fluckiger and weterhalter or micro column chromatography. 
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An on-chip electrochemical flow immunoassay system for the detection of 
hemoglobin A1C (HbA1C) was developed using anti-human hemoglobin 
(Hb) IgG labeled with ferrocene monocarboxylic acid (Fc–COOH) and 
boronate-affinity chromatography. 
 
Drawback:  
 GDM however may not present with the same constant elevation of 
blood sugar levels as in non pregnant states. Gravid women with GDM 
have fasting blood sugar concentration that are low, because of increased 
erythropoiesis, red blood cells are younger in pregnancy, haemoglobin is 
less glycated and hormonal milieu changing rapidly from relative insulin 
sensitivity to that of insulin resistance as the pregnancy progresses.  
 Artal et al and course et al investigated glycosylated haemoglobin as 
a screening test and found to have very low sensitivity and specificity. Its 
measurement shows better correlation to the degree of glycemic control in 
the past 2 to 3 months.  
 Glycosylated HbA1c is often elevated in diabetes and the magnitude 
of the elevation correlates inversely with the degree of long term control of 
plasma concentration. 
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HbA1C: 
 Mean HbA1c levels are closely correlated to all meal related glucose 
measurements during pregnancy. It is therefore a reliable indicator of 
overall glycemic control among patients with diabetes during pregnancy. 
(Gandhi RA, BrownJ, Simma). 
 If the screening test for gestational DM was delayed, HbA1C level 
and the risk for LGA seemed to be higher, so it may be necessary to screen 
GDM no later than 24th week of pregnancy. (Choi yJ, Kahng J) 
 Shah et al measured HbA1C using ion exchange chromatography 
and applied NDDG criteria for GDM in a group of patients with risk factor 
for it. This test is mainly used to predict the risk of embryopathy. HbA1C 
>8.5% is associated with 20-25% probability of fetal developmental 
abnormalities. When the value is normal the probability of major 
malformation is <2%. These data do not support the use of HbA1C as a 
screening test for GDM.  
3.Serum Fructosamine test:  
 Fructosamine assay was proposed as a screening test for the 
identification of women at risk for diabetes. Fructosamine is associated with 
glycemic control over the previous 1 to 3 weeks, so it can be used as an 
appropriate maker for GDM. However this test is less sensitive than glucose 
challenge test (SHAH BD, COHEN AW et al) 1982.  
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The values of serum fructosamine are it expressed as follows:  
 Good diabetic control <300 mol/1 
 Satisfactory control 300 – 400 mol/l 
 Poor control >400mol/l 
4.Urine sugar Test: 
 Glycosuria is a commonly employed screening test for detection of 
glucose intolerance. But during pregnancy the renal threshold for glucose is 
often lowered  due to an eight fold increase in golmerular filtration of 
glucose and an intermittent tubular defect in glucose reabsorption.  
 This had led to the observation of long Hint (1923) that glycosuria 
following oral glucose load in a woman who has missed her period can be 
used as a test for pregnancy (federsen et al) An awareness of this fact can 
lead to an under diagnosis of glucose intolerance during pregnancy, while a 
lack of it will result in over diagnosis.  
 However the specificity of glucosura can be increased by defining 
significant glucosuria which occurs in second fasting morning specimen of 
urine (SUTTERCAND HWSTOWERS IM et al 1970) Pregnant women 
with renal glycosura are at high risk of premature delivery (25%) and fetal 
macrosomia 7% (CHEN et al) 
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Diagnostic tests for GDM: 
 1.100g 3 hour oral glucose tolerance test  
 2.75g 2 hr. oral glucose tolerance test  
 3. IV glucose tolerance test  
 
Oral glucose tolerance test:  
 Patient should be instructed to have unrestricted diet (atleast 150 gm 
carbohydrate per day) and unrestricted physical activity for 3 days before 
the test and advised to come after an overnight fasting. This will minimize 
the false positive results (Journal OBS and gynae vol 70 NO-1) After taking 
blood for FBS. Patient is advised to drink glucose water (100 grams in 300 
ml of water) Hourly blood sample should be taken for 3 hour.  
GDM is diagnosed if two or more value are abnormal. If one value is 
abnormal, the patient cannot be diagnosed as having GDM, but they are 
prone for complications like macrosomia and preeclampsia.  
Proposed criteria for OGTT during pregnancy 
Time Osullivan 
Mahan 
(Blood) 
NDDG(1979) 
Plasma 
Carpenter 
and counstan 
(1982) 
Marketz et al 
1980 
F 90 105 95 105 
1 hr 165 190 180 185 
2 hr 143 165 159 140 
3 hr 127 145 140 125 (with 75 
gms glucose) 
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 Patient in high risk group should have GTT done in early pregnancy 
as possible and if they have a normal glucose tolerance, the test should be 
repeated at 30 weeks gestation. At this gestational age the diabetogenic 
effect of Pregnancy is near its peak and the chances of a positive result from 
GTT are high. OGTT is borderline a repeat examination to confirm the 
diagnosis is made.  
 In 0’sullivan studies whole blood was tested using somogyi nelson 
method for measuring reducing substance. Patient with glucose tolerance 
test results fall between carpenter and coustan and NDDG criteria  have the 
same probability of insulin treatment (26%) as those meeting NDDG 
criteria (30%) and the same probability of macrosomia.  
 
WHO GTT: 
 In contrast to north America, much of the rest of world uses 75 g oral 
GTT during pregnancy, according to criteria adopted by world health 
organization. 
Time Normal DM GDM (Mg/d1) 
Fasting 2 hrs 
after glucose 
<110 
<160 
<140mg% 
>200mg% 
<140 
<140-200 
            
Intermediate readings are classified as impaired glucose tolerance. 
The diagnostic criteria for diabetes in pregnancy are more stringent than 
26 
 
those recommended for non pregnant subjects and pregnant women with 
IGT should be treated as diabetes.  
 
IVGTT: 
 It was adapted for use in pregnancy by silver stone et al. IVGTT 
offer some theoretic advantages over oral GTT. The k value allows easier 
analysis of glucose tolerance data and is in most  circumstances 
independent of the method of glucose determination and is unaffected by 
variation in gastric emptying.  
 If an intravenous GTT is to be performed 0.5g of glucose / kg of 
ideal body weight is administered iv in 2 min or less blood glucose 
determination are made before the infection and at 10min interval  for the 
following hour. These 6 plasma glucose determination are used to construct 
a graph.  The time taken for the blood glucoses live to fall to half of its 
value (  t ½ ) is used to calculate the absolute glucose disappearance rate (k) 
k value is calculated  using the formula K=0.693 /t ½ x 100 K value of < 
1.5 indicates abnormal glucose tolerance.  
 The lower limit of normal for k in the first trimester was 137 in the 
second trimester 1.18 and in the third trimester 1.13 valuve below this level 
were regarded as abnormal.  
 The oral test is more practical for out patients and is better at 
estimating the efficiency of glucose disposed in patient with mild 
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abnormalities of glucose tolerance. In addition  intestinal factors appears to 
have an effect on normal insulin response and oral glucose ingestion 
represents the normal route for carbohydrate absorption. It should be 
pointed out that the IVGTT is useful in patients with gastrointestirial that 
may make the result of their oral test misleading.  
 Abnormal glucose tolerance during pregnancy has been associated 
with poor fetal outcome with identification and treatment of the same. 
Reliance upon risk factors for screening has been found to be unsatisfactory 
as the chances of missing a diagnose is around 50%. 
 Hence it is concluded that universal screening of all pregnant 
subjects must be undertaken. Irrespective of the nature of AGT subjects 
must be followed up till delivery, post partum GTT must be done to 
recognise true DM and AGT can recur during subsequent pregnancies.  
 In my study I have chosen HbA1c as a predictor of abnormal OGTT 
in Ist and 2nd trimester and its correlation with abnormal fetal outcome.  
 
Adverse effects of Diabetes: 
 Maternal complications:  
 Diabetic complication includes hypoglycemia, diabetic ketoacidosis, 
retinopathy, neuropathy, nephropathy and heart diseases. Comparison of 
specific compication in diabetic and non diabetic pregnancies as per various 
studies given below:  
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Complication Diabetic Control Reference 
PIH 16 7.7 Rosenn et al 
Hypertension 2.5 0.3 Suhonens Terano 
Hydramnios 2 0.7 Gotoman et al 
Pyelonephritis 3.6 1.4 Rosenn et al 
Preterm 31 20 Mimouni et al 
Preterm delivery 24.6 6 Hansenc person et al 
Caesarean section 45.2 12 Hanson & person 
Post caesarean 
section infection 13.4 3.2 Diamond et al 
 
 
MATENAL MORTALITY:  
 The composite maternal mortality rate of 0.14% was reported. To 
minimize the matemal mortality in addition to medical and obstetric case 
given antenatally. More comprehensive preconception medical evaluation 
and patient education are imperative.  
 
FETAL COMPLICATIONS:  
 Fetus born to diabetic mother have a wide range of structural and 
biochemical abnormalities that can be reduced or eliminated by improved 
control of maternal glucose metabolism.  
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 Fetal complications are macrosomia, congenital malformation, 
respiratory distress syndrome, hypoglycemia, placental immaturity and 
infarcts, umbilical cord edema and single umbilical artery, polycythemia / 
hyperviscosity syndrome, hyperbilirubinemia ,cardiomyopathy, small left 
colon syndrome.  
 
Fetal Evaluation:  
 The perinatal mortality due to GDM has diminished markedly with 
more thorough screening programmes and intense surveillance of glycemia 
antepartum monitoring. Antepartum surveillance with weekly, nonstresstest 
and blood glucose monitoring to maintain fasting plasma glucose below 150 
mg/d1 helps in diminishing perinatal mortality. The  most important fetal 
complications are macrosomia, congenital malformation respiratory distress 
syndrome and sudden intrautenine death.  
 
Macrosomia:  
 Macrosomia has been variously defined as birth weight greater than 
4000 to 4500 g as well as large for gestational age with birth weight above 
90th percentile for population specific and sex specific growth curves, which 
complicates as many as fifty percent of pregnancies in women with  
GDM (MEFARLAND MB, LANGER O et, al, 2000). 
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PEDERSON HYPOTHESIS:  
Maternal 
Hyperglycemia 
Maternal 
hyperamino 
acidemia    Fetal hyperglycemia 
 
Fetal hyperamino  Fetal pancreatic hyperplasia 
acidemia 
 
 
 
                                      TOTAL HYPERINSULINEMIA 
 
 
 Macrosomia     Organomegaly                              Increased       Surface fant   
                        eg : liver, heart                             Erythropoesis     Production 
 
Traumatic                Neonatal hypoglycemia, Hyaline Membrane Disease,  
vaginal delivery    Nematal Polycythemic  Hyper viscosity syndrome  
 
Perinatal mortality rate of 0.49% and the perinatal morbidity of 11.4% in 
infants weighing more than 4000 gm is five times more than of   non  
macrosomic  pregnancies.  
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PRENATAL DIAGNOSIS OF MACROSOMIA:  
 If the abdominal circumference measurement at 28-29 weeks of 
gestation by ultrasonogram is one centimeter or above the mean value at 
that stage of pregnancy, there is 77% likely hood of fetal macrosomia. If the 
EFW is above 90th percentile macrosomia can occur in 74% of cases. 
However, the head circumference and BPD measurements were less 
predictive of macrosomia.  
Predictors of shoulder dystocia:  
 One of the avoidable complication of macrosomia is shoulder 
dystocia. Modanlou et al have shown that an ultrasound derived chest to 
head circumference difference of 1.6 cm or a shoulder to head 
circumference difference of 4.8 cm predict shoulder dystocia, especially if 
there is an abnormality in maternal glucose tolerance.  
Management:  
 Obviously the optimal management approach for macrosomia is 
prevention.  Since macrosomia depends mainly upon the post prandial 
glucose level we should maintain at the optimal level through appropriate 
management. An elective cesarean delivery should be performed for an 
estimated fetal weight of 4000 gm or more. Most of the trails have 
demonstrated that prophylactic insulin therapy can in fact reduce the 
incidence of macrosomia as well as perinatal mortality.  
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 O’sullivan et al in 1966 tried prophylactic insulin. He randomized 
women with two groups 305 were treated with prophylactic insulin and 306 
constituted as untreated control groups. A third cohort of 328 non-diabetic 
pregnant women served as normal controls. O’sullivan et al found that 13% 
of the untreated women with GDM gave birth 70 babies weighing more 
than 4.1 kg compared with 4% of normal gravid women and a subsequent 
reanalysis of the data showed the insulin treatment was associated with a 
significant reduction in perinatal mortality rate (O’sulvivan JB, Mahan en et 
al, 1974). 
Respiratory Distress Syndrome:  
IDM’s are prove to RDS incidence . The factors influencing are:  
1. Insulin may delay the fetal lung maturation in two ways.  
a. Through direct action on type II pneumocyts via increased insulin 
recepors and  
b. indirectly via lung fibroblasts.  
2. Hyperglycemia: 
a. Decreases bio availability of important precussors for 
phospholipids production and surfactant protein modification. 
b. Decreased  number of type II alveolar cells. 
c. Decreased number of type II cell lamellar bodies.  
d. Decreased production of phosphotidyl choline and phosphotidyl 
glycerol.  
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3. Increased beta hydroxybutyrate inhibit surfactant protein expression in 
fetal lung.  
4. The delayed appearance of phosphotidyl glycerol in amniotic fluid in 
diabetic pregnancy is due to increased fetal myoinositol occurring as a 
result of maternal hyperglycemia. 
Congenital Anomalies in infants of Diabetic mothers:  
• Skeletal and central nervous sytem 
• Caudal regression syndrome 
Neural tube defects 
  
• Anencephaly 
Gastrointestinal: 
• Duodenal atresia 
• Anorectal atresia 
• Small left colon syndrome 
• Single umbilical artery 
Cardiac 
• VSD 
• Coarctation 
• Cardiac septal hypertrophy 
• Transposition of great vessels  
Renal anomalies: 
• Hydronephrosis  
• Renal agenesis 
• ureteral duplication  
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Pathogenesis:  
 Embryos exposed to the metabolic derangement during the period of 
organogenesis are at increased risk of teratogenic insult.  
 Glycosylation of protein and abnormal vasculare observed in 
hyperglycemia leads to tissue under perfusion of the Embryo resulting in 
consequent hypoxia, acidosis cell injury and congenital malformation. The 
abnormalities in yolk sac tissue which is the site of origin of epithelium of 
many embryonic organ lead to developmental defect in these organ. 
 The experimental use of several different compounds such as 
arachidonic acid, myoinositol and antoaxidants (HOD met al, 1986) offer 
promise for the fetus as prophylactie against diabetic embryopathy.  
 Unlike in women with overt diabetes fetal anomalies are not 
increased in GDM. 
 The issue of GDM being associated with congenital anomalies is 
controversial prospective studies have suggested the possibility of increased 
rates of malformations in offspring of women with GDM. Adarshi et al in 
18 month study surveyed 113 diabetic pregnancies and found that rate of 
congenital malformation was 6.3 in offspring of diet controlled GDM 
group, compared with no malformation in offspring of women with either 
GDM or pregestational diabetes receiving insulin.  
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 Congenital malformations of the fetus produce a major financial and 
social business to the parent and the society. Prevention to a greater extent 
demands adequate periconceptional counseling.  
Perinatal mortality and material mortality:  
 Before insulin became available in 1922 pregnancy and diabetes 
were seen as a deadly combination.  
 In 1882, Mathew Deencan of Fordan reported that out of 22 
pregnancies into diabetic mother 4 mothers died at the time of labour 
another 7 died with in 2 years and nearly half the children were either born 
dead (or) died shortly thereafter (DUNCAN MJ et al 18820. 
 In this decade after insulin discovery maternal mortality rate has 
been reduced drastically from 50% to 0.5%. 
 Perinatal outcome is mainly influenced by maternal blood glucose 
level, obtaining maternal euglycemic remains the yardstick in the 
management.  
Perinatal mortality rate/maternal blood glucose:   
Average blood glucose (mg/01)       <100                100-150         >150 
PNMR                            3.4%      16%          24% 
 Improved fetal surveillance neonatal intensive care and maternal 
metabolic control have reduced perinatal losses to 2 to 4%. These rates have 
seemingly plateaued because the two major causes of fetal death. 
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Congenital malformations and unexplained fetal death remain challenging 
to the medical personals (GARNER). 
Summary of literature:  
 In any high risk pregnancy obstetric outcome is mainly influenced by 
maternal and perinatal outcome obstetric outcome in diabetic mothers can 
be improved by early detection and effective management. Hence universal 
screening of antenatal mother for diabetes is mandatory.  
Discussion : 
 Gestational Diabetes Mellitus (GDM) is associated with increased 
perinatal and maternal mortality and morbidity, which can be plummeted by 
early detection through screening and effective management.  
 Compared to European population, prevalence of GDM has 
increased eleven fold in women from Indian subcontinent (DORNHURST, 
1992). Various studies conducted in India showed varying prevalence 
depending upon the population sample and the diagnostic criteria.  
Prevalence of GDM in Indian subcontinent  
Authors Year Prevalence 
Agarwal et al 1982 1.88% (North Indian) 
Samanta et al 1989 0.18% 
Dornhurst et al 1992 4.4% 
Ramachandran et al 1994 0.56% (South Indian) 
C.Battacharya et al  2001 3% 
Abha Jindal et al 2001 9% 
Present study  2.4% 
 
37 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 
To study the HbA1c in abnormal OGCT in 1st and 2nd trimester and its 
correlation with abnormal fetal outcome.  
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MATERIAL AND METHODS 
 
TYPE OF STUDY: Descriptive study. 
STUDY PLACE:  
DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY, ISO-KGH, 
MADRAS MEDICAL COLLEGE, CHENNAI. 
 At the time of first antenatal visit all pregnant women are clinically 
evaluated by a detailed history and a proper general, system, obstetric 
examination and oral glucose challenge test (OGCT). Among them 500 
patients with abnormal OGCT will be enrolled for the study. These patients 
are analysed further by HbA1C and ultrasonogram examination during 1st 
and 2nd trimester. After study is completed, the various levels of HbA1C are 
interpreted in terms of maternal and fetal outcome.  HbA1C is measured by 
an on-chip electrochemical flow immunoassay method.  
  HbA1C <6% is desirable for pregnancy. Pregnancy with HbA1C 
>9% is advised termination. Those with HbA1C between 6-9% is correlated 
with USG findings and further management decided. If no abnormality 
detected the mother is advised for further management regarding gestational 
Diabetes mellitus (GDM). All the patients will be provided with routine 
antenatal care till delivery. 
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Statistical Tools (To be included at the end of Materials and Methods)  
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2010) 
developed by Centre for Disease Control, Atlanta.  
 Using this software range, frequencies, percentages, means, standard 
deviations, chi square and  'p'  values were calculated. Kruskul Wallis chi-
square  test was used to test the significance of difference between 
quantitative variables and Yate’s chi square test for qualitative variables. A 
'p' value less than 0.05 is taken to denote significant relationship. 
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RESULTS 
A: PROFILE OF CASES STUDIED 
TABLE 1: AGE DISTRIBUTION 
 
Cases Age group 
No % 
< 20 years  10 2.0 
20 – 24 years 188 37.6 
25 – 29 years 235 47.0 
30 & above  67 13.4 
Total 500 100 
Range 19 – 36 years 
Mean 25.7 years 
SD 3.5 years 
 
500 women in the age group of 19 – 36 years were included in the study. 
Their mean age was 25.7 years and standard deviation was 3.5 years. 
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TABLE 2 : GESTATION AGE 
Cases Age group 
No % 
< 20 weeks 155 31.0 
20 – 24 weeks 265 53.0 
25 – 28 weeks 80 16.0 
Total 500 100 
Range 13-27 weeks 
Mean 21.2 weeks 
SD 3.3 weeks 
 
 31% of woman had a gestational age of less than 20 weeks, 53% had 
20-24 weeks and 16% had 25 – 28 gestational weeks. The group had a 
mean of 21.2 weeks of gestation at the time of HbA1C estimation. 
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TABLE 3: OBSTETRIC CODE 
Cases Obstetric code 
No % 
Primi 170 34 
Multi 330 66 
Total 500 100 
 
170 women (34%) included in the study were primis and the 
remaining 66% were multi gravida. 
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TABLE 4: USG FINDINGS 
 
Cases 
 
USG result 
No % 
NS 496 99.2 
Anomalous 4 0.8 
 
 There were 4 ( 0.8%) anomalous cases as per USG findings. 
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TABLE 5 : GCT 
Parameter GCT ( mg/dl) 
Range 140-152 
Mean 145.5 
SD 2.5 
 
The study group had a GCT value of 145.5+2.5 mg/dl. 
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TABLE 6: HbA1C % 
Cases HbA1C 
No % 
Normal ( < 6.5%) 493 98.6 
Abnormal ( > 8.5%) 7 1.4 
Total 500 100 
Range 5.1% - 7.7% 
Mean 5.65% 
S.D. 0.33 % 
 
 Among the 500 women studied only 7 mothers (1.4%) had an 
abnormal HbA1C value. The group had HbA1C value of 5.65 + 0.33%. 
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TABLE 7: FETAL OUTCOME 
Cases Fetal outcome 
No % 
Good 490 98 
Termination 10 2 
Total 500 100 
    Among the women studied, 98% had good fetal outcome. 
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     CHART 7: FETAL OUTCOME 
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B: RELATIONSHIP BETWEEN HBA1C AND FETAL OUTCOME 
 
TABLE 8: HbA1C AND FETAL OUTCOME 
 
Fetal outcome 
Good Termination 
HbA1C No.of cases 
No % No % 
Normal 493 484 98.2 9 1.8 
Abnormal 7 6 85.7 1 14.3 
HbA1C% 
Mean 
SD 
 
5.64 
0.32 
 
5.91 
0.75 
‘p’ 0.1326 
Not significant 
 
 Among mothers with normal HbA1C values, there were 9 
terminations and in mothers with abnormal HbA1C one termination. The 
mean HbA1C values were 5.64 for those with good fetal outcome and 5.91 
for those with abnormal outcome. These differences were not statistically 
significant ( p = 0.1326).  
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C : RELATIONSHIP BETWEEN OTHER VARIABLES AND 
FETAL OUTCOME 
TABLE 9: AGE AND FETAL OUTCOME 
Age in years Fetal outcome 
Mean SD 
Good 25.7 3.5 
Termination 25.1 3.8 
‘p’ 0.5641  
Not significant 
 Age of mothers did not have significant relationship with fetal 
outcome    ( p > 0.05). 
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CHART 9:  AGE AND FETAL OUTCOME 
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TABLE 10: OBSTETRIC CODE AND FETAL OUTCOME 
Fetal outcome 
Good Termination 
Obstetric 
code 
No.of 
cases 
No % No % 
Primi 170 166 97.6 4 2.4 
Multi 330 324 98.2 6 1.8 
‘p’ 0.459 
Not Significant 
 Among primis, 97.6% had good fetal outcome and among multis 
98.2% had good outcome. This relationship was not statistically significant 
( p = 0.459). 
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TABLE 11: GCT AND FETAL OUTCOME 
GCT ( mg/dl) Fetal outcome 
Mean SD 
Good 145.5 2.5 
Termination 145.3 3.1 
‘p’ 0.5696 
Not Significant 
 Mothers with poor fetal outcome had GCT of 145.3 +3.1 and 
mothers with good outcome had GCT of 145.5+ 2.5). The relationship was 
not statistically significant. 
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DISCUSSION 
Elevated HbA1C is associated with increased adverse pregnancy 
outcomes (eg abortion , stillbirth, and congenital abnormalities. However, a 
level of AIC below which further improvement will carry no benefit for the 
fetus has not been defined.  
1. Korean J Lab med. 2009 Apr; 29 (2): 110-5 The relationship between the 
timing of gestational diabetes screening and HbA1C level and neonatal 
outcome.  
2. Zhong Narda xue xue ba yi xue ban 2008 Jan; 33(1); 85.8 
Glycosylated hemoglobin test in gestational abnormal glucose metabolism. 
According to several studies there seems to be a family broad range 
(up to around 10SDS above the reference level) of acceptable metabolic 
control around conception over which the risk of acceptable AIC values. 
suhonen et al found that even a slightly raised AIC level was positively 
associated with an increased risk of major congenital abnormalities. We 
likewise found no indication of such an AIC threshold level, but our risk 
estimates were imprecise due to a small number of adverse outcomes. Low 
level of AIC can only be achieved at the cost of an increased risk of 
hypoglycemia episodes, which are often feared by both patients and 
doctors, therefore it is of interest to establish whatever there exists an AIC 
threshold below which further reduction will not improve fetal prognosis. 
63 
 
SUMMARY 
In our present study 500 antenatal women with abnormal glucose 
challenge test in first and second trimester had been selected and subjected 
to HbA1C estimation. 
Among the 500 women studied only 7 mothers had an abnormal 
HbA1C value 6 had good fetal outcome which accounts for 85.7% and 1 
had abnormal fetal outcome which accounts for 14.3% 
The mean HbA1C  values were 5.64 for those with good fetal 
outcome and 5.91 for those with abnormal outcome these differences were 
not statically significant. 
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CONCLUSION 
 
In our present study 500 antenatal women with abnormal glucose 
challenge test in first and second trimester had been selected and subjected 
to HBA1C estimation. 
The study revealed  HbA1C   is not a good predictor for GDM with 
adverse  fetal outcomes. 
Hence the study HbA1C is not a marker for GDM with congential 
anomalies. 
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PROFORMA 
 
 NAME 
 AGE 
 SOCIO ECONOMIC STATUS 
 ADDRESS 
 GRAVIDITY 
 LMP 
 EDD 
 MENSTRUAL H/O 
 MARITAL H/O 
 OBSTETRIC H/O 
 PAST H/0 
 
 
GENERAL EXAMINATION 
 
 
 PULSE RATE 
 BLOOD PRESSURE 
 ANAEMIA 
 PEDAL EDEMA 
 BREAST 
 THYROID 
 SPINE 
 PER ABDOMEN 
 PERVAGINUM 
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MASTER CHART 
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1 LAKSHMI 25 3014 G2P1L1 13 145 6 NS GOOD 
2 AMBIKA 24 3088 PRIMI 20 148 5.2 NS GOOD 
3 GRACE 22 3725 PRIMI 21 143 6 NS. GOOD 
4 SHEEBA 28 3645 G3A2 24 148 5.6 NS GOOD 
5 LALITHA 32 3212 G2P1L0 23 149 5.2 NS GOOD 
6 LILLY 29 3423 PRIMI 26 145 5.7 NS GOOD 
7 JEBA 21 7625 G2A1 24 142 5.3 NS GOOD 
8 RAMYA 24 3545 PRIMI 23 146 5.4 NS GOOD 
9 FATHIMA 23 3654 G2P1L0 24 149 5.7 NS GOOD 
10 PRIYA 24 3767 G3P2L1 26 145 5.8 NS GOOD 
11 DEVI 27 3645 PRIMI 22 143 5.4 ANOMALOUS TERMINATION 
12 ANNAM 21 3256 G2P1L1 26 148 5.6 NS GOOD 
13 VEMBU 25 3897 G2A1 25 143 5.7 NS GOOD 
14 KANIKA 21 3745 PRIMI 24 150 5.2 NS GOOD 
15 VANI 32 3264 PRIMI 25 151 6.7 NS GOOD 
16 NITHIYA 36 2546 G2P1L1 24 143 5.7 NS GOOD 
17 RAJI 26 3612 PRIMI 26 145 5.9 NS GOOD 
18 DIVIYA 19 3765 G2A1 24 142 5.3 NS GOOD 
19 PUSHPA 23 3243 G3P2L2 23 147 6.2 NS GOOD 
20 USHA 27 3906 PRIMI 26 148 5.7 NS GOOD 
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21 MARIAM 24 3712 G2P1L1 25 147 5.1 NS GOOD 
22 ANITHA 27 3456 G2P1L1 24 146 5.6 NS GOOD 
23 AMBIKA 21 2434 PRIMI 26 143 5.2 NS GOOD 
24 SATHIYA 21 3762 PRIMI 21 142 5.3 NS GOOD 
25 VANI 27 3154 G3P1L1A
1 
23 145 5.4 NS GOOD 
26 MANJU 33 3651 G2A1 27 150 5.8 NS GOOD 
27 RAJI 22 3871 G2A1 24 143 5.4 NS GOOD 
28 KUMARI 19 3908 PRIMI 26 147 5.6 NS GOOD 
29 NATHIYA 23 3710 PRIMI 26 149 5.6 NS GOOD 
30 KOWSEI 26 3004 G2P1L1 24 148 5.3 NS GOOD 
31 KAIALB 21 3612 G4A3 23 146 5.2 NS GOOD 
32 BHARTHI 24 3817 G2A1 25 143 5.1 NS GOOD 
33 THARANI 32 3945 G3P1L1A
1 
25 150 5.4 NS GOOD 
34 KGUMARI 24 3732 PRIMI 24 146 5.5 NS GOOD 
35 ANITHA 21 3767 PRIMI 23 145 5.2 NS GOOD 
36 SUJI 26 3434 G3A2 24 145 5.1 NS GOOD 
37 VALI 19 3624 G2P1L1 24 143 5 NS GOOD 
38 REMYA 28 3898 G2A1 24 147 6.7 NS GOOD 
39 SHYNI 28 3909 G2P1L0 25 148 5.3 NS GOOD 
40 BLESSY 19 3709 G2P1L1 26 145 5.2 NS GOOD 
41 JAMILA 22 3203 G2A1 23 146 5.3 NS GOOD 
42 MALIKA 27 3150 PRIMI 21 146 5.4 NS GOOD 
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43 SHANTHI 32 3265 PRIMI 27 146 5.8 NS GOOD 
44 JAYA 20 4512 G2P1L1 25 143 5.4 NS GOOD 
45 MARY 30 2369 PRIMI 21 142 5.5 NS GOOD 
46 MALI 19 5125 PRIMI 23 147 5.3 NS GOOD 
47 RAJI 22 2356 G2A1 25 146 5.6 NS GOOD 
48 SHEELA 28 2969 G2P1L1 24 149 5.6 NS GOOD 
49 RAGA 24 1569 G3P1L1A
1 
26 143 5.6 NS GOOD 
50 AJIM 26 2365 PRIMI 27 148 5.7 NS GOOD 
51 JAYA 27 4865 PRIMI 23 142 5.4 NS GOOD 
52 ELAVARASI 25 2314 PRIMI 25 147 5.5 NS GOOD 
53 LENI MARY 22 1856 G2A1 24 145 5.9 NS GOOD 
54 JANCY 26 5369 G2P1L1 24 145 5.8 NS GOOD 
55 ALMELU 28 4236 G3P2L2 26 146 5.6 NS GOOD 
56 SHALINI 29 2658 G2P1L1 25 145 5.2 NS         GOOD 
57 RATHNA 26 2159 G2P1L1 25 147 5.2 NS GOOD 
58 SIVRANJANI 32 3698 PRIMI 26 147 5.5 NS GOOD 
59 JANCYRANI 34 2489 PRIMI 23 148 5.6 NS GOOD 
60 KALIVANI 22 2178 PRIMI 23 145 5.8 NS GOOD 
61 NANTHINI 26 2695 G2A1 24 143 5.3 NS GOOD 
62 KANMANI 29 3125 G3P1L1A
1 
25 145 5.1 NS GOOD 
63 SAROJA 25 3254 PRIMI 25 142 5.3 NS GOOD 
64 GAYATHRI 32 2985 G2P1L1 24 143 6 NS GOOD 
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65 KAVITHA 24 2569 G2P1L1 26 149 5.4 NS GOOD 
66 KANIKA 29 2489 G3A2 23 147 5.4 NS GOOD 
67 CLARA 27 2658 G2A1 27 147 5.4 NS GOOD 
68 SHEELA 21 2478 PRIMI 24 145 5.3 NS GOOD 
69 THARA 23 2698 PRIMI 25 146 5.6 NS GOOD 
70 PUSPHA 21 3124 PRIMI 23 145 5.6 NS GOOD 
71 THARA 24 3276 G2P1L1 16 141 5.5 NS GOOD 
72 SOBANA 32 2145 PRIMI 24 145 5.7 NS GOOD 
73 KAVIYA 34 2458 G2A1 27 145 5.7 NS GOOD 
74 LAKSHMI 32  PRIMI 25 140 5.7 NS GOOD 
75 KIRTHEEKA 26 2698 PRIMI 25 143 5.4 NS GOOD 
76 JAYANTHI 28 2478 G2P1L1 24 148 5.3 NS GOOD 
77 SOLOKCHANA 26 3248 G2A1 24 148 5.2 NS GOOD 
78 SUGANTHI 21 3125 G3P1L1 21 149 5.2 NS GOOD 
79 MALARGODI 25 4865 G3P2L2 23 145 4.9 NS GOOD 
80 RAVATHI 26 2985 PRIMI 26 147 5.2 NS GOOD 
81 SUGANYA 23 2487 PRIMI 25 146 5.3 NS GOOD 
82 RATHIKA 24 2698 G2A1 24 143 5.4 NS GOOD 
83 SANGEETHA 21 2147 G2A1 24 148 5.4 NS GOOD 
84 CHANDRA 29 2985 G2P1L0 23 148 5.9 NS GOOD 
85 MANGALA 26 3248 PRIMI 24 148 5.6 NS GOOD 
86 MANOGARI 24 2145 G2P1L1 27 147 5.5 NS GOOD 
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87 SUBULAKSHIMI 25 2487 G3P2L2 26 149 5.5 NS GOOD 
88 JAYALAKSHM 23 1265 PRIMI 23 146 5.4 NS GOOD 
89 RAJALAKSHMI 25 1478 G2P1P1 24 146 5.3 NS GOOD 
90 NATHIYA 29 2698 G2P1L1 24 143 5.6 NS GOOD 
91 DIVYA 21 3214 PRIMI 24 143 5.5 NS         GOOD 
92 KALAYANI 26 2358 PRIMI 25 143 5.2 NS GOOD 
93 CHITHRA 32 1698 PRIMI 25 146 5.3 NS GOOD 
94 KAVITHA 34 3985 PRIMI 24 148 5.4 NS GOOD 
95 KRISHNAVENI 31 1956 G2A1 27 147 5.4 NS GOOD 
96 ANUSHYA 26 1265 G2P1L1 23 146 5.3 NS GOOD 
97 PRIYA 24 1598 G2P1L1 26 145 5.1 NS GOOD 
98 AMMU 29 2589 PRIMI 25 143 5.8 NS GOOD 
99 ANIJA 24 1325 PRIMI 25 147 5.9 NS GOOD 
100 PONMANI 27 2698 G2A1 26 147  5.2 NS GOOD 
101 SEETHA 29 2985 .PRIMI 14 142 5.1 NS GOOD 
102 RANI 25 1698 .G2P1L1. 14 I45 6.5 NS GOOD 
103 SUDHA 21 1789 PRIMI 16 141 5.7 NS POOR 
104 KAMACHI 26 2536 .G2A1. 16 143 5.9 NS GOOD 
105 ROSI 24 4289 G3P2L2 18 142 5.1 NS GOOD 
106 SANTHA 23 3269 G2P1L0 13 149 5.9 NS GOOD 
107 LAVANYA 24 2564 PRIMI 22 141 5.7 NS GOOD 
108 SWEETY 25 3254 G2P1L1 24 146 5.1 NS GOOD 
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109 PRADEEPA 22 2541 PRIMI 18 142 5.2 NS GOOD 
110 RENUGA 25 2985 PRIMI 18 140 5.6 NS GOOD 
111 ANITHA 29 2415 G2AI 16 148 6 NS GOOD 
112 SAVEETHA 24 2365 G3P1L1A
1 
24 147 5.2 NS GOOD 
113 BARANI 26 2896 G2P1L1 18 143 5.9 NS. GOOD 
114 PAVITHRA 28 3256 G2P1L1 20 141 5.3 NS GOOD 
115 RAJAKUMARI 26 2487 PRIMI 14 145 5.1 NS GOOD 
116 DEEPA 32 1568 G3P2L2 19 142 6 NS GOOD 
117 MUNIYAMMA 29 1267 G3P2L2 20 141 5.8 NS GOOD 
118 ANNAMALAI 22 2359 G2P1L1 22 145 5.2 NS GOOD 
119 KASTURI 24 3256 G2P1L1 20 142 5.6 NS GOOD 
120 SELI 23 1258 G3A2 18 143 5.9 NS GOOD 
121 NARMATHA 26 1478 PRIMI 16 141 5.7 NS GOOD 
122 AMBIKA 24 2698 PRIMI 16 142 6 NS GOOD 
123 SARITHA 29 2369 G2P1L1 20 142 5.2 NS GOOD 
124 DAHNALAKSHMI 31 1498 G3P2L1 22 147 5.8 NS GOOD 
125 SATHYA 25 2541 G2P1L1 22 146 6 NS GOOD 
126 MAGESHWARI 20 3012 PRIMI 19 141 5.5 NS GOOD 
127 UMA 26 2158 PRIMI 22 144 5.5 NS GOOD 
128 VIJAYALAKSH 25 1478 G2P1L1 18 152 9.7 ANAMOLOUS TERMINATION 
129 SHYLAJA 23 2569 PRIMI 14 141 5.1 NS GOOD 
130 SRIDEVI 29 3256 G2P1L1 16 142 6 NS GOOD 
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131 MALATH 24 3842 G2A1 16 149 5.3 NS GOOD 
132 SATHYAPRIYA 25 2147 G3P2L1 20 145 5.6 NS GOOD 
133 KOSALYA 26 2145 G3P2L2 22 146 5.8 NS GOOD 
134 MALAR 28 1698 G2P1L1 20 142 5.6 NS GOOD 
135 DEVIPRIYA 20 2589 PRIMI 24 147 5.8 NS GOOD 
136 VANI 31 1523 G4P3L1 20 143 5.9 NS GOOD 
137 INDU 32 1473 G2P1L1 22 149 5.7 NS GOOD 
138 RAGA 26 2594 G2P1L1 16 145 5.6 NS GOOD 
139 RAGAMATH 
NISHA 
28 2386 G2P1L1 18 142 5.9 NS GOOD 
140 RASATHI 25 3086 G3A2 18 143 5.6 NS GOOD 
141 PADMA 26 2853 G2P1L1 20 146 5.8 NS GOOD 
142 BAKYA 24 2586 G2P1L1 22 143 5.5 NS GOOD 
143 PARAMESHWARI 28 2185 G3P2L2 22 144 5.6 NS GOOD 
144 VALAR 21 2954 G2P1L1 24 143 5.8 NS GOOD 
145 MURUGESHWARI 22 3258 G2A1 22 142 5.9 NS GOOD 
146 SUNDARI 25 2145 G2P1L1 20 145 5.7 NS GOOD 
147 PODUMPONA 23 2698 G2P1L1 18 149 5.5 NS GOOD 
148 MANIMEGALAI 21 2478 PRIMI 22 147 5.5 NS GOOD 
149 GANASUNDARI 22 2563 G2A1 21 145 5.6 NS GOOD 
150 UMA 23 3021 PRIMI 24 146 5.9 NS GOOD 
151 VENODINI 26 3589 G2P1L1 22 148 5.7 NS GOOD 
152 PRABA 29 2145 G3P2L2 20 146 5.6 NS GOOD 
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153 IYAMMA 31 2658 G4P3L1 20 149 5.9 NS GOOD 
154 UNNAMALI 31 3021 G2P1L1 18 143 5.7 NS GOOD 
155 CHELLAMMA 30  G2P1L1 20 144 5.8 NS GOOD 
156 RADIKA 26 2136 G2P1L1 14 145 5.9 NS GOOD 
157 SASIKALA 29 2863 G3P2L2 20 146 5.6 NS GOOD 
158 PONGODI 24 2154 G2P1L1 16 147 5.4 NS GOOD 
159 USHA RANI 25 2031 G2P1L1 18 145 5.6 NS GOOD 
160 KAMACHI 29 3025 G3P2L1 16 148 5.6 NS GOOD 
161 ARULMOZIL 28 1203 PRIMI 18 142 5.8 NS GOOD 
162 MARVIZLI 32 2691 G2A1 20 146 5.6 NS GOOD 
163 GOMATHIDEVAKI 25 2013 G2P1L1 22 143 5.8 NS GOOD 
164 RAMANI 26 2325 G2P1L1 18 145 5.8 NS GOOD 
165 VENILA 21 2486 G2P1L1 16 148 5.6 NS GOOD 
166 MYTHILI 28 2148 G3P2L2 22 149 5.5 NS GOOD 
167 RENUKA 29 2963 G3P1L1 20 147 5.2 NS GOOD 
168 AMUTHA 21 3058 G2A1 24 141 5.1 NS GOOD 
169 KARPAKAM 24 3045 G2P1L1 16 142 5.3 NS GOOD 
170 MEEANKSHI 25 1258 G2P1L1 24 148 5.4 NS GOOD 
171 RASATHI 26 1632 G2P1L1 20 143 5.8 NS GOOD 
172 KANAMMA 28 2147 G3P2L2 22 146 5.9 NS GOOD 
173 KUMUTHA 24 2369 PRIMI 24 145 5.7 NS GOOD 
174 RANI 26 2541 PRIMI 16 145 5.6 NS GOOD 
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175 RAMA 21 3086 PRIMI 18 143 5.5 NS GOOD 
176 KUMARI 20 2147 G2P1L1 22 141 5.3 NS GOOD 
177 MANIMEGALI 26 3621 G2P1L1 24 142 5.7 NS GOOD 
178 SIVAGAMI 21 1205 PRIMI 20 149 5.8 NS GOOD 
179 SUSILLA 25 1682 G2P1L1 16 148 5.9 NS GOOD 
180 ESWARI 26 2698 G2A1 18 147 5.5 NS GOOD 
181 THENMIZOHI 21 3258 PRIMI 18 143 5.5 NS GOOD 
182 JAMUNA 23 1258 G3P1L1 20 146 5.8 NS GOOD 
183 VASANTHI 28 2596 G2P1L1 24 142 5.6 NS GOOD 
184 SETALLA 24 3254 G2P1L1 20 145 5.8 NS GOOD 
185 VIJAYA 21 1286 PRIMI 24 150 5.6 NS GOOD 
186 HEMAVATHI 20 3256 PRIMI 16 141 5.5 NS GOOD 
187 JEROM 22 1586 G2P1L1 14 143 5.6 NS GOOD 
188 CELLIN 30 2158 G2P1L1 20 144 5.4 NS GOOD 
189 SUSEELA 31 3589 G3P2L2 22 149 5.8 NS GOOD 
190 JANAKI 26 1258 G2P1L1 18 147 5.4 NS GOOD 
191 SUDHA 25 1698 G3P2L2 24 146 5.2 NS GOOD 
192 PARVEEN 21 3258 G2A1 22 142 5.6 NS GOOD 
193 DURGADEVI 23 2145 PRIMI 20 147 5.4 NS GOOD 
194 AYSHA 28 1586 G3A2 18 146 5.7 NS GOOD 
195 INDUMATHI 26 3698 G2P1L1 16 142 5.9 NS GOOD 
196 BAKYAVATHI 24 1258 G2P1L1 18 141 5.1 NS GOOD 
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197 VALLI 21 1263 G2P1L1 16 140 5.6 NS GOOD 
198 SALIMA 29 3248 G3P2L1 20 143 5.7 NS GOOD 
199 BOMMI 25 1526 PRIMI 22 145 5.6 NS GOOD 
200 FLORA 23 3698 G2P1L1 24 142 5.7 NS GOOD 
201 AKSHYA 31 2148 G4P2L2A
1 
22 146 5.9 NS GOOD 
202 JEEBA 28 1589 G2P1L1 20 147 5.3 NS GOOD 
203 BEGAM 24 2365 PRIMI 18 149 5.8 NS GOOD 
204 INDRANLEKA 25 1258 G2P1L1 16 143 5.9 NS GOOD 
205 CHANDRA 26 1693 G2P1L1 20 148 5.6 NS GOOD 
206 SHAJEETHJA 21 2485 PRIMI 16 147 5.9 NS GOOD 
207 ASLIMA 29 2569 G2P1L1 18 149 5.6 NS GOOD 
208 PANCHAYAMMA 31 3014 G3P2L2 16 143 5.9 NS GOOD 
209 NARKIESS BANU 30 2563 G2P1L1 20 148 5.6 NS GOOD 
210 MANGAYAR 
ARASI 
23 2485 PRIMI 24 145 5.8 NS GOOD 
211 MAHALAKSHMI 33 1258 G3P2L2 18 147 5.7 NS GOOD 
212 KALPANA 29 3021 G3P2L2 16 146 5.6 NS GOOD 
213 GANDIMATHI 24 1250 G2P1L1 14 143 5.9 NS GOOD 
214 VEDAVALLI 20 1243 PRIMI 20 141 5.3 NS GOOD 
215 RASATHI 29 2635 G2P1L1 22 143 5.6 N S GOOD 
216 MUTHU 32 1258 PRIMI 18 146 5.8 NS GOOD 
217 RAJANI 26 1369 G2P1L1 18 146 5.7 NS GOOD 
218 BALA 21 2569 PRIMI 16 143 5.9 NS GOOD 
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219 ANALAKSHMI 24 3256 G2P1L1 14 146 6 NS GOOD 
220 GIRIJA 26 3025 G2P1L1 18 149 5.1 NS GOOD 
221 JERCY 29 3058 G3P2L2 20 149 5.9 NS GOOD 
222 DAICY 25 3025 G2P1L1 22 143 5.7 NS GOOD 
223 PARIMALA 30 1526 G3P2L1 20 145 5.8 NS GOOD 
224 SUMITHRA 31 1478 G3P2L1 20 146 5.6 ANAMOLOUS TERMINATED 
225 PRAMA 21 1269 PRIMI 24 143 5.9 NS GOOD 
226 ARTHIA 26 2589 PRIMI 22 148 6 NS GOOD 
227 ABIRAMI 25 3254 G2P1L1 20 146 5.9 NS GOOD 
228 MUBINA AZIM 21 2458 G2P1L1 22 142 5.8 NS GOOD 
229 NAGALASHMI 24 1589 G2A1 24 145 5.8 NS GOOD 
230 JOTHI 26 1269 PRIMI 18 150 5.3 NS GOOD 
231 MANGAI 21 3256 PRIMI 16 146 5.8 NS GOOD 
232 MANJULA 28 1478 G2P1L1 14 145 5.7 NS GOOD 
233 GEETHA 29 3025 G2P1L1 16 147 5.6 NS GOOD 
234 PRABAVATHI 30 3069 G3P2L2 18 148 5.5 NS GOOD 
235 LAITHA 22 2589 PRIMI 20 149 5.4 NS GOOD 
236 SENBAGAM 24 3214 G2P1L1 22 147 5.7 NS GOOD 
237 ANANDHI 25 2019 G2P1L1 24 146 5.8 NS GOOD 
238 KOKILA 26 2365 G2P1L1 20 145 5.6 NS GOOD 
239 LALITHA 32 2563 G3A2 22 146 5.7 NS GOOD 
240 JASMINE 21 2369 PRIMI 20 147 5.9 NS GOOD 
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241 SAGAYAM 25 2563 G2A1 24 149 5.9 NS GOOD 
242 TAMILSELVI 30 1698 G3P2L1 22 143 5.5 NS GOOD 
243 ELAKYA 25 2365 G2P1L1 16 144 5.7 NS GOOD 
244 BARANI 24 2147 PRIMI 18 145 5.4 NS GOOD 
245 BALA 28 2569 G3P2L1 22 145 5.6 NS GOOD 
246 PECHI 21 1258 PRIMI 20 143 5.7 NS GOOD 
247 SHARMILASENAK
A 
30 1369 G2P1L1 16 148 5.9 NS GOOD 
248 MUMTAJ 20 3210 G2P1L1 18 145 5.6 NS GOOD 
249 PONGAVANA 25 2147 G2A1 22 148 5.8 NS GOOD 
250 JENITHA 26 3256 G2P1L1 20 147 5.6 NS GOOD 
251 REENA 24 1528 G2A1 16 143 5.5 NS GOOD 
252 SOLOMI 25 2598 G2P1L1 14 148 5.7 NS GOOD 
253 RANI 26 2158 G2P1L1 21 147 5.8 NS GOOD 
254 REVATHI 26 1569 G2P1L1 16 141 6.5 NS GOOD 
255 MUNIYAMMA 28 2485 G3P2L1 20 146 5.1 NS GOOD 
256 LAVANYA 26 1478 G3P2L2 18 148 4.2 NS GOOD 
257 JOTHIKA 29 2589 G3P2L2 20 147 5.8 NS GOOD 
258 SARANYA 30 1747 PRIMI 17 142 5.9 NS POOR 
259 PONKOLALI 24 1569 PRIMI 21 148 5.5 NS GOOD 
260 REKHA 27 2589 G2A1 22 147 5.4 NS GOOD 
261 THILAKAVATHI 20 3256 G3P2L2 16 145 5.2 NS GOOD 
262 PUSHPALATHA 29 1478 G2P1L1 17 149 5.6 NS GOOD 
85 
 
S.
No
 
NA
M
E 
AG
E 
IP
NO
 
O
BS
TE
TR
IC
 
CO
DE
 
G
ES
TA
TI
O
NA
L 
 
 
AG
E(
W
EE
KS
)  
G
CT
 
 
m
g/
dl
 
Hb
A1
C 
(%
) 
US
G
 
O
UT
CO
M
E 
263 PONMANI 24 1256 G3P2L2 21 147 5.9 NS GOOD 
264 RASAMMA 28 2589 G2P1L1 22 149 5.8 NS GOOD 
265 RAVATHI 27 2458 G2A1 18 147 5.5 NS GOOD 
266 MURUGAMMA 23 1478 G3P1L1 19 145 5.7 NS GOOD 
267 RAKI 30 1569 G2P1L1 21 142 5.9 NS GOOD 
268 JANANI 31 3256 G2p1l1 23 146 5.1 NS GOOD 
269 FATIMA 34 3589 G5p4l3 16 143 5.2 NS GOOD 
270 SHABEENA 28 1247 G2p1l1 19 148 5.5 NS GOOD 
271 SHAN 25 1589 G2a1 18 149 5.4 NS GOOD 
272 REVATHI 29 2698 G2P1L1 20 147 5.3 NS GOOD 
273 REHIMA 26 3147 G2P1L1 22 146 5.9 NS GOOD 
274 MANGALAM 29 1258 G3A2 16 142 5.8 NS GOOD 
275 INDIRA 31 1789 G2P1L1 18 147 5.6 NS GOOD 
276 FARITHA BANU 32 3698 G3A2 20 143 5.8 NS GOOD 
277 RASATHI 28 2563 PRIMI 23 147 5.1 NS GOOD 
278 THASEEN 29 1478 G2P1L1 22 145 5.4 NS GOOD 
279 SANTHA 30 2589 G3P2L2 24 148 5.5 NS GOOD 
280 MARY 24 3258 PRIMI 16 149 5.2 NS POOR 
281 ROHINI 28 1478 G2P1L1 18 142 6 NS GOOD 
282 REKHA 29 2589 G2P1L1 21 146 5.5 NS GOOD 
283 REVATHI 24 3256 PRIMI 16 141 5.5 NS GOOD 
284 JERINA 20 1896 G2P1L1 18 145 5.7 NS GOOD 
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285 TEENA 24 2596 G2P1L1 19 148 5.9 NS GOOD 
286 HEMAVATHI 21 1478 PRIMI 17 147 5.8 NS GOOD 
287 MOHAN 25 3259 G2P1L1 20 146 6 NS GOOD 
288 REUNUKADEVI 29 1478 G3P2L2 23 149 5.2 NS GOOD 
289 SOMUNDESHWAR
I 
25 2596 PRIMI 22 147 5.4 NS GOOD 
290 SAGAYAM 28 3698 G2P1L1 24 146 5.2 NS GOOD 
291 VANITHA 30 2365 G3P2L2 21 145 6.5 NS GOOD 
292 GOWRI 29 2147 G3P2L2 17 143 5.1 NS GOOD 
293 BHAVANI 24 3698 PRIMI 19 142 5.6 NS GOOD 
294 SUGANDI 26 2147 G2P1L1 17 149 5.7 NS GOOD 
295 RANJITHA 28 1589 PRIMI 18 148 5.9 NS GOOD 
296 VASANTHI 26 2563 G3A2 16 145 5.5 NS GOOD 
297 ESWARI 21 3698 G2P1L1 21 149 5.6 NS GOOD 
298 RENU 28 1478 G2P1L1 23 147 5.8 NS GOOD 
299 SHALIMMA 24 2569 G2P1L1 21 148 5.7 NS GOOD 
300 DEEPA 27 1426 G3P1L1A
1 
19 146 5.5 NS GOOD 
301 ELAYARASI 25 2569 PRIMI 17 142 5.9 NS GOOD 
302 RAGARANI 30 2145 G2P1L1 16 143 5.8 NS POOR 
303 JAYANTHI 28 3315 G2P1L1 20 141 5.6 NS GOOD 
304 MALATHI 21 2478 PRIMI 23 149 5.8 NS GOOD 
305 ROHINI 24 1589 PRIMI 22 148 5.6 NS GOOD 
306 RATHA 29 1478 G2P1L1 20 147 5.9 NS GOOD 
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307 CHANDRIKA 25 1369 G2P1L1 23 145 5.8 NS GOOD 
308 MUTHULAKSHIMI 29 2658 G3P2L1 16 146 5.8 NS GOOD 
309 THANGAM 24 3698 G2P1L1 19 142 6 NS GOOD 
310 ELAMMA 21 1254 PRIMI 18 143 5.5 NS GOOD 
311 MALATHI 25 1584 G2P1L1 16 147 5.4 NS GOOD 
312 MALAVI 30 1478 PRIMI 19 149 5.2 NS GOOD 
313 SHARMILA 31 2547 PRIMI 18 145 5.1 NS GOOD 
314 SANGAVIROJA 28 2698 G2P1L1 17 146 6 NS GOOD 
315 PONNI 26 3258 G2P1L1 18 143 5.5 NS GOOD 
316 THENMOZHIS 24 1478 PRIMI 20 142 5.6 NS GOOD 
317 KALAIYARASI 32 5478 G3P2L2 23 148 5.9 NS GOOD 
318 VANI 21 6985 PRIMI 21 149 5.8 NS GOOD 
319 KARISHNAVENI 25 2145 G2P1L1 19 145 5.1 NS GOOD 
320 SHANTHI 24 1458 G2P1L1 17 147 5.7 NS GOOD 
321 JASMINE 26 2569 G2P1L1 18 149 4.1 NS GOOD 
322 JAYA 28 2478 G3P2L2 20 145 6 NS GOOD 
323 NASEEMA 21 3258 PRIMI 16 146 5.5 NS GOOD 
324 NAGALAKSHMI 24 3698  18 145 5.6 NS GOOD 
325 MEENA 26 2145 G2P1L1 19 148 5.9 NS GOOD 
326 GAYATHRI 28 2458 G2P1L1 17 149 5.7 NS GOOD 
327 RENUKA 21 1589 PRIMI 20 145 6 NS GOOD 
328 KANIMOZHI 23 1478 PRIMI 23 142 5.6 NS GOOD 
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329 RENU 28 1369 G3P2L2 21 143 6 NS GOOD 
330 ROSHMA 24 2145 G2P1L1 23 149 5.5 NS GOOD 
331 ELAVARASI 29 2458 G3P2L2 22 148 5.6 NS POOR 
332 SARMILA 26 1258 G2P1L1 24 147 5.1 NS GOOD 
333 SULOKSANA 24 2365 PRIMI 19 142 6 NS GOOD 
334 MANIMALA 28 2478 G2P1L1 18 143 6 NS GOOD 
335 GOVINDAMMA 27  G2P1L1 16 145 5.5 NS GOOD 
336 NIRMALA 21 1254 G2P1L1 17 149 5.6 NS GOOD 
337 VIJI 30 1589 G3P2L2 19 147 5.9 NS GOOD 
338 PRIYA 31 3697 G2P1L1 20 146 5.6 NS GOOD 
339 SREYA 25 2589 G2P1L1 21 145 6 NS GOOD 
340 STELLA 26 1478 G3A2 18 148 5.3 NS GOOD 
341 POONIMA 28 1369 G2P1L1 19 147 6 NS GOOD 
342 NANTHINI 21 1452 PRIMI 18 145 5.9 NS GOOD 
343 SUSEELA 24 1254 G2P1L1 17 142 5.1 NS GOOD 
344 SUJITHA 27 1256 G2P1L1 20 143 5.9 NS GOOD 
345 JOTHI 25 1232 PRIMI 23 146 5.2 NS GOOD 
346 ANALAKSHMI 29 1265 G3P2L1 21 149 5.5 NS GOOD 
347 MANGAYARKARA
SI 
23 1452 PRIMI 22 148 6 NS GOOD 
348 MANIMAGALAI 24 1452 PRIMI 24 146 5.9 NS GOOD 
349 JENIFER 21 1265 PRIMI 19 149 5.7 NS GOOD 
350 YASMINE 25 1524 G2P1L1 18 147 5.5 NS GOOD 
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351 YOGALAKSHMI 32 1265 G3P2L1 17 142 5.8 NS GOOD 
352 MANJULA 21 1542 PRIMI 16 143 5.7 NS GOOD 
353 ANJALI 25 1426 G2P1L1 21 146 5.9 NS GOOD 
354 AROKYAMARY 28 1246 G3P2L2 24 148 6 NS GOOD 
355 AMSAVENI 24 1426 PRIMI 19 147 5.1 NS GOOD 
356 MEEAKSHI 26 1246 G2P1L1 18 149 5.5 NS GOOD 
357 BABY 21 1426 PRIMI 20 142 5.2 NS GOOD 
358 SUDARKODI 24  PRIMI 23 149 5.4 NS GOOD 
359 MANIMEGALAI 23 1452 G2P1L1 21 147 5.8 NS GOOD 
360 TAMIL 21 1524 PRIMI 20 142 5.5 NS GOOD 
361 KOKILA 24 1452 G2P1L1 23 148 6 NS GOOD 
362 MARY 28 1453 G2P1L1 16 149 5.2 NS GOOD 
363 MUTHULAKSHMI 24 1265 G2P1L1 24 142 5.6 NS GOOD 
364 SRIDEVI 26 1365 G3P2L2 18 145 5.4 NS GOOD 
365 TAMARAI SE 28 1364 G3P2L2 20 147 5.6 NS GOOD 
366 RANI 25 1326 PRIMI 19 148 5.9 NS GOOD 
367 MUNIYAMMA 20 1263 PRIMI 16 149 5.8 NS GOOD 
368 RAGAVI 25 1325 G2P1L1 20 142 5.6 NS GOOD 
369 NAMITHA 26 1236 G2P1L1 19 147 5.7 NS POOR 
370 SHAKILA 23 1524 PRIMI 21 146 5.9 NS GOOD 
371 SALOMIYA 25 1265 G2P1L1 23 148 5.8 NS GOOD 
372 BAVANI 21 2145 PRIMI 19 142 5.6 NS GOOD 
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373 BHARANI 32 2195 G3P2L2 18 141 5.5 NS GOOD 
374 LALLLU 26 2587 G2P1L1 21 149 5.6 NS GOOD 
375 LAVANYA 28 1256 G2P1L1 22 145  5.4 NS GOOD 
376 MAGESHVARI 25 3256 PRIMI 20 147 6 NS GOOD 
377 KALYANI 29 2155 G2P1L1 21 142 5.3 NS GOOD 
378 VELAMMMAL 25 1478 PRIMI 23 148 5.2 NS GOOD 
379 KANNIGA 24 2145 G2P1L1 21 142 5.9 NS GOOD 
380 VALAR 25 2478 PRIMI 19 141 5.7 NS GOOD 
381 VIJAYA 29 3256 G2P1L1 18 143 5.6 NS GOOD 
382 KOKILA 24 1478 PRIMI 17 149 6 NS GOOD 
383 VENDA 28 1562 G2P1L1 20 147 5.6 NS GOOD 
384 VALARMATHY 24 4569 PRIMI 18 145 5.1 NS GOOD 
385 VIJAYALASHMI 26 2145 PRIMI 17 148 5.8 NS GOOD 
386 SUNDARI 29 2547 G2P1L1 18 142 5.5 NS GOOD 
387 KANMANI 21 1458 PRIMI 20 147 5.2 NS GOOD 
388 GAYATHRI 22 2598 PRIMI 22 146 5.1 NS GOOD 
389 MYTHILI 24 1458 G2P1L1 19 149 6 NS GOOD 
390 DHANAM 25 2369 G2P1L1 18 148 5.5 NS GOOD 
391 SIVAGAMI 28 2154 G3P2L2 23 145 5.9 NS GOOD 
392 KANCHANA 29 1478 G2P1L1 24 142 5.7 NS GOOD 
393 REVATHI 24 1458 PRIMI 18 149 5.6 NS GOOD 
394 SANGAVI 25 1478 G2P1L1 17 147 5.9 NS GOOD 
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395 RENU 26 1895 G2P1L1 20 145 5.7 NS GOOD 
396 NISH 21 1245 PRIMI 16 149 5.8 NS GOOD 
397 BABY 25 2458 G2P1L1 20 147 6 NS GOOD 
398 MUMTAJ 21  PRIMI 18 142 5.5 NS GOOD 
399 KANIYAMMA 24 1458 G2P1L1 19 146 5.8 NS GOOD 
400 JAYANTHI 26 1425 G2P1L1 21 141 5.9 NS GOOD 
401 MALAR 24 2548 PRIMI 23 145 6 NS GOOD 
402 KUMARI 32 2654 G3P2L2 18 149 5.3 NS GOOD 
403 GANTHIMATHI 30 2148 G2P1L1 17 148 5.5 NS GOOD 
404 MALATHI 25 2158 PRIMI 22 142 5.8 NS GOOD 
405 SELVI 26 1547 G2P1L1 20 146 5.9 NS GOOD 
406 SHANTHI 28 1598 G2P1L1 19 141 5.8 NS GOOD 
407 NOORBI 29 1289 G3P2L2 17 148 6.1 NS GOOD 
408 MASTHAN 24  PRIMI 23 143 5.3 NS GOOD 
409 PADMAVATHI 25 1547 PRIMI 21 149 5.5 NS GOOD 
410 GIRIJA 22 1358 PRIMI 20 145 5.9 NS GOOD 
411 POLAMMAL 21 1298 PRIMI 19 147 6 NS GOOD 
412 LAKSHMI 25 3014 G2P1L1 13 145 4.8 NS GOOD 
413 AMBIKA 24 3088 PRIMI 20 148 5.2 NS GOOD 
414 GRACE 22 3725 PRIMI 21 143 6 NS. GOOD 
415 SHEEBA 28 3645 G3A2 24 148 5.6 NS GOOD 
416 LALITHA 32 3212 G2P1L0 23 149 5.2 NS GOOD 
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417 LILLY 29 3423 PRIMI 26 145 5.7 NS GOOD 
418 JEBA 21 7625 G2A1 24 142 5.3 NS GOOD 
419 RAMYA 24 3545 PRIMI 23 146 5.4 NS GOOD 
420 FATHIMA 23 3654 G2P1L0 24 149 5.7 NS POOR 
421 PRIYA 24 3767 G3P2L1 26 145 5.8 NS GOOD 
422 DEVI 27 3645 PRIMI 22 143 5.4 NS GOOD 
423 ANNAM 21 3256 G2P1L1 26 148 5.6 NS GOOD 
424 VEMBU 25 3897 G2A1 25 143 5.7 NS GOOD 
425 KANIKA 21 3745 PRIMI 24 150 5.2 NS GOOD 
426 VANI 32 3264 PRIMI 25 151 5.7 NS GOOD 
427 NITHIYA 36 2546 G2P1L1 24 143 5.7 NS GOOD 
428 RAJI 26 3612 PRIMI 26 145 5.9 NS GOOD 
429 DIVIYA 19 3765 G2A1 24 142 5.3 NS GOOD 
430 PUSHPA 23 3243 G3P2L2 23 147 5.2 NS GOOD 
431 USHA 27 3906 PRIMI 26 148 5.7 NS GOOD 
432 MARIAM 24 3712 G2P1L1 25 147 5.3 NS GOOD 
433 ANITHA 27 3456 G2P1L1 24 146 5.6 NS GOOD 
434 AMBIKA 21 2434 PRIMI 26 143 5.2 NS GOOD 
435 SATHIYA 21 3762 PRIMI 21 142 5.3 NS GOOD 
436 VANI 27 3154 G3P1L1A
1 
23 145 5.4 NS GOOD 
437 MANJU 33 3651 G2A1 27 150 5.8 NS GOOD 
438 RAJI 22 3871 G2A1 24 143 5.4 NS GOOD 
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439 KUMARI 19 3908 PRIMI 26 147 5.6 NS GOOD 
440 NATHIYA 23 3710 PRIMI 26 149 5.6 NS GOOD 
441 KOWSEI 26 3004 G2P1L1 24 148 5.3 NS GOOD 
442 KAIALB 21 3612 G4A3 23 146 5.2 NS GOOD 
443 BHARTHI 24 3817 G2A1 25 143 5.1 NS GOOD 
444 THARANI 32 3945 G3P1L1A
1 
25 150 5.4 NS GOOD 
445 KGUMARI 24 3732 PRIMI 24 146 5.5 NS GOOD 
446 ANITHA 21 3767 PRIMI 23 145 5.2 NS GOOD 
447 SUJI 26 3434 G3A2 24 145 5.8 NS GOOD 
448 VALI 19 3624 G2P1L1 24 143 5.5 NS GOOD 
449 REMYA 28 3898 G2A1 24 147 5.1 NS GOOD 
450 SUBBAMMAL 23 1452 PRIMI 22 148 6 NS GOOD 
451 JOYCE 24 1452 PRIMI 24 146 5.9 NS GOOD 
452 RENGANAYAGI 21 1265 PRIMI 19 149 5.7 NS GOOD 
453 SHYNI 28 3909 G2P1L0 25 148 5.3 NS GOOD 
454 BLESSY 19 3709 G2P1L1 26 145 5.2 NS GOOD 
455 JAMILA 22 3203 G2A1 23 146 5.3 NS GOOD 
456 MALIKA 27 3150 PRIMI 21 146 5.4 NS GOOD 
457 SHANTHI 32 3265 PRIMI 27 146 5.8 NS GOOD 
458 JAYA 20 4512 G2P1L1 25 143 5.4 NS GOOD 
459 MARY 30 2369 PRIMI 21 142 5.5 NS GOOD 
460 MALI 19 5125 PRIMI 23 147 5.3 NS GOOD 
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461 RAJI 22 2356 G2A1 25 146 5.6 NS GOOD 
462 SHEELA 28 2969 G2P1L1 24 149 5.6 NS GOOD 
463 RAGA 24 1569 G3P1L1A
1 
26 143 5.6 NS GOOD 
464 AJIM 26 2365 PRIMI 27 148 5.7 NS GOOD 
465 JAYA 27 4865 PRIMI 23 142 5.4 NS GOOD 
466 ELAVARASI 25 2314 PRIMI 25 147 5.5 NS GOOD 
467 LENI MARY 22 1856 G2A1 24 145 5.9 NS GOOD 
468 JANCY 26 5369 G2P1L1 24 145 5.8 NS GOOD 
469 ALMELU 28 4236 G3P2L2 26 146 5.6 NS GOOD 
470 SHALINI 29 2658 G2P1L1 25 145 5.3 NS GOOD 
471 RATHNA 26 2159 G2P1L1 25 147 5.2 NS GOOD 
472 SIVRANJANI 32 3698 PRIMI 26 147 5.5 NS GOOD 
473 JANCYRANI 34 2489 PRIMI 23 148 5.6 NS GOOD 
474 KALIVANI 22 2178 PRIMI 23 145 5.8 NS GOOD 
475 NANTHINI 26 2695 G2A1 24 143 5.3 NS GOOD 
476 KANMANI 29 3125 G3P1L1A
1 
25 145 5.1 NS GOOD 
477 SAROJA 25 3254 PRIMI 25 142 5.3 NS GOOD 
478 GAYATHRI 32 2985 G2P1L1 24 143 5.2 NS GOOD 
479 KAVITHA 24 2569 G2P1L1 26 149 5.4 NS GOOD 
480 KANIKA 29 2489 G3A2 23 147 5.4 NS GOOD 
481 CLARA 27 2658 G2A1 27 147 5.4 NS GOOD 
482 SHEELA 21 2478 PRIMI 24 145 5.3 NS GOOD 
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483 THARA 23 2698 PRIMI 25 146 5.6 NS GOOD 
484 LEELAVATHI 21 3112 PRIMI 23 145 5.7 NS GOOD 
485 THANGAMMA 24 3276 G2P1L1 16 141 5.5 NS GOOD 
486 SOBANA 32 2145 PRIMI 24 145 5.7 NS GOOD 
487 KAVIYA 34 2458 G2A1 27 145 5.7 NS GOOD 
488 KIRTHEEKA 26 2698 PRIMI 25 143 5.4 NS GOOD 
489 JAYANTHI 28 2478 G2P1L1 24 148 5.3 NS GOOD 
490 SOLOKCHANA 26 3248 G2A1 24 148 5.2 NS GOOD 
491 SUGANTHI 21 3125 G3P1L1 21 149 5.2 NS GOOD 
492 MALARGODI 25 4865 G3P2L2 23 145 5.9 NS GOOD 
493 RAVATHI 26 2985 PRIMI 26 147 5.2 NS GOOD 
494 SUGANYA 23 2487 PRIMI 25 146 5.3 NS GOOD 
495 RATHIKA 24 2698 G2A1 24 143 5.4 NS GOOD 
496 SANGEETHA 21 2147 G2A1 24 148 5.4 NS GOOD 
497 CHANDRA 29 2985 G2P1L0 23 148 5.9 NS GOOD 
498 MANGALA 26 3248 PRIMI 24 148 5.6 NS GOOD 
499 SELVI 28 2890 PRIMI 22 147 5.4 NS GOOD 
500 GEETHA 25 3345 PRIMI 24 143 5.6 NS GOOD 
 
 
 
 
